Rapid escalation of cholesterol-lowering treatment to prevent repeat heart events
Official title: Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event (REDUCE) : All Comers Study
Run by Chinese University of Hong Kong · NCT07311941 · Data updated 2026-11-12
This project will try frequent LDL-C checks and quicker increases in lipid-lowering medicines for adults with recent or chronic coronary artery disease to help them reach LDL goals and reduce repeat heart problems.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Shatin, New Terrritories) |
| Status | Recruiting |
| Started | December 30, 2024 |
| Main results expected | December 31, 2030 |
| Study ends | June 30, 2031 |
| Registry record updated | December 31, 2025 |
| Trial ID | NCT07311941 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with atherosclerotic acute coronary syndrome or chronic coronary syndrome who can provide informed consent are the intended participants.
✕Probably not a fit
Patients with non-atherosclerotic causes of ACS, life expectancy under six months, severe psychiatric or neurological disorders, or cirrhosis may not receive benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry will follow adults with atherosclerotic acute coronary syndrome or chronic coronary syndrome and implement more frequent LDL-C monitoring with earlier titration of lipid-lowering therapy. Participants will have repeat blood tests around 6–8 weeks after medication changes and clinicians will adjust statins and add-on non-statin agents as needed. The registry will record adherence, treatment changes, LDL-C levels over time, and recurrent cardiovascular events in a real-world hospital setting. The work is led by the Chinese University of Hong Kong at Prince of Wales Hospital and aims to address local barriers such as therapeutic inertia and limited resources.
Why it matters
Potential benefit: If successful, this approach could help patients reach LDL-C targets sooner and lower their risk of repeat heart attacks or other cardiovascular events.
How similar studies have gone: Randomized trials have shown that intensive LDL-C lowering reduces cardiovascular events, but programs that focus on rapid, frequent monitoring and titration in routine clinical practice are less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 * (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease * (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease Exclusion Criteria: * Inability to provide valid consent by the patient or his legal guardian * Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease. * Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \< 6 months.
Where it's running
-
Prince of Wales Hospital
Shatin, New Terrritories, Hong Kong Recruiting
Study contacts
- Study coordinator: Guangming Tan
- Email: xjldaniel@gmail.com
- Phone: 852-35051518
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Enlicitide (MK-0616) for adults with high cholesterol in India
This study tests whether enlicitide helps lower bad cholesterol (LDL-C) compared with placebo in adults with hyperlipidemia/hypercholesterolemia.
-
HRS-7249 extension study for people with high triglycerides
This extension study tests whether repeat injections of HRS-7249 are safe and keep triglyceride levels low in adults who previously completed the parent study or have high fasting triglycerides.
-
Platelets and plasma lipids as markers and targets in thrombosis
This study tests whether two lipid emulsion formulations change platelet clumping in healthy volunteers age 40 and up who do not have heart disease.
-
Bacillus subtilis and Enterococcus faecium Probiotic Plus Lipid-Lowering Therapy for HTG-AP
This trial tests whether adding a probiotic capsule to standard lipid-lowering therapy helps people with mild HTG-AP see lower triglycerides and better recovery.
-
EHR-guided LDL cholesterol optimization after a heart event
A pharmacist-guided program using electronic health records to help adults in Alberta reach LDL goals after a heart event by adjusting medications and ordering tests.
-
Spermidine supplement for lipid and weight changes in adults with obesity and high cholesterol
This study tests whether taking spermidine daily for 1 month can improve blood lipids and body weight in adults who are overweight or obese with high cholesterol, while monitoring safety.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.